Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 4Recruiting 3Active not recruiting 3Not yet recruiting 2Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Myelodysplastic Syndromes 1

Interventions

Specimen Handling 17Biopsy 12Magnetic Resonance Spectroscopy 10Cyclophosphamide 9venetoclax 5Etoposide 4Azacitidine 4fludarabine phosphate 3fludarabine 3durvalumab 3X-Rays 3Tacrolimus 3Paclitaxel 3Interleukin-2 3Gemcitabine 3Cisplatin 3Carboplatin 3zanubrutinib 2prednylidene 2deltacortene 2aldesleukin 2Vincristine 2Taxes 2Stem Cell Transplantation 2Rituximab 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Protein Subunit Vaccines 2Prednisone 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Suspended × Photons × Clear all
NCT06888323 2026-04-13

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
Myeloid

Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡